Spago Nanomedical's lead candidate Tumorad are progressing towards initial results by mid-2024 and Pegfosimer Manganese (SpagoPix) has progressed to a stage where Spago Nanomedical can engage with potential partners. The OPEX base is contained at SEK 12m in Q4.
LÄS MER